Search
Xanthan gum
go.drugbank.com/drugs/DB11253ApprovedXanthan gum is a direct food additive permitted for direct addition to food for human consumption by the FDA. It is used as a thickening agent and stabilizer in emulsions. … Xanthan gum is a polysaccharide gum derived from* Xanthomonas campestris* by a pure-culture fermentation process and purified by recovery with isopropyl alcohol.
Cholecystokinin
go.drugbank.com/drugs/DB08862ApprovedInvestigationalWithdrawnNormally, it is an endogenous hormone but is available commercially for diagnostic processes and replacement in pancreatic insufficiency [L1646, L1647, L1648]. in the octapeptide form. … Cholecystokinin, previously called _pancreozymin_, is synthesized and secreted by enteroendocrine cells in the duodenum (the first portion of the small intestine) and leads to the release of bile and digestive
Birch bark extract
go.drugbank.com/drugs/DB16536ApprovedInvestigational[L42390] Filsuvez was subsequently approved for the same indication by the US FDA in December 2023. … [L50031] The EMA marketing authorization for Episalvan[L42370] was withdrawn by the manufacturer in 2022.
Aminohippuric acid
go.drugbank.com/drugs/DB00345ApprovedInvestigationalWithdrawnIts sodium salt is used as a diagnostic aid to measure effective renal plasma flow (ERPF) and excretory capacity. [PubChem]
Synonyms: N-(p-Aminobenzoyl)glycine, N-(para-aminobenzoyl)glycineCilostazol
go.drugbank.com/drugs/DB01166ApprovedInvestigationalIt is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions.
Baricitinib
go.drugbank.com/drugs/DB11817ApprovedInvestigational[L41760] Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults [A248395] and was later approved by the FDA in 2018. … By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses.
Perampanel
go.drugbank.com/drugs/DB08883ApprovedInvestigationalIt is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures.
Bivalirudin
go.drugbank.com/drugs/DB00006ApprovedInvestigationalOnce bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. … Because it can cause blood stagnation, it is important to monitor changes in hematocrit, activated partial thromboplastin time, international normalized ratio and blood pressure.
Mangafodipir
go.drugbank.com/drugs/DB06796ApprovedInvestigationalWithdrawnTeslascan has been removed from the Drug Product List by FDA in 2003, and withdrawn from the European market in 2012. … Enhanced contrast by mangafodipir improves visualization and detection of lesions of the liver formed from metastatic disease or hepatocellular carcinomas.
Inositol nicotinate
go.drugbank.com/drugs/DB08949ApprovedWithdrawnIt is associated with reduced flushing compared to other vasodilators by being broken down into the metabolites and inositol at a slower rate. … Inositol nicotinate, also known as Inositol hexaniacinate/hexanicotinate or "no-flush niacin", is a niacin ester and vasodilator.